Posted by Michael Wonder on 14 Feb 2019
Universal medicine access through lump-sum remuneration — Australia’s approach to hepatitis C
14 February 2019 - Australia’s agreement to spend about 1 billion Australian dollars (U.S.$766 million) over 5 years in exchange for an unlimited volume of hepatitis C drugs suggests that, under certain conditions, innovative approaches to payment can remove price as a barrier to access.
